Real-World Comparative Effectiveness of Abiraterone, Apalutamide, Enzalutamide, and Docetaxel Doublets for Metastatic Hormone-Sensitive Prostate Cancer.
PURPOSE To evaluate the real-world comparative effectiveness of androgen receptor pathway inhibitors (ARPIs)-abiraterone, apalutamide, enzalutamide-and docetaxel, plus androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). METHODS We identified US men with mHSPC who initiated ADT...